ArticleBiomaterials2010
The attenuation of central angiotensin II-dependent pressor response and intra-neuronal signaling by intracarotid injection of nanoformulated copper/zinc superoxide dismutase.
Article in Biomaterials, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 74 citations in OpenAlex.
- Statin therapy lowers muscle sympathetic nerve activity and oxidative stress in patients with heart failure.American journal of physiology. Heart and circulatory physiology · 2012Trial
- pH-responsive nanozymes: multifunctional platforms for biomedical catalysis toward clinical translation.Frontiers in bioengineering and biotechnology · 2026Review
- The Pathophysiology of Alcohol-Associated Liver Disease: Focusing on Superoxide Dismutase 1 as a Therapeutic Target.Biology · 2025Review
- Sympathoinhibition and Vasodilation Contribute to the Acute Hypotensive Response of the Superoxide Dismutase Mimic, MnTnBuOE-2-PyPAdvances in redox research · 2021Article
- Comparative EPR Study on the Scavenging Effect of Methotrexate with the Isomers of Its Photoswitchable Derivative.Pharmaceuticals (Basel, Switzerland) · 2021Article
- The Role of Nanomaterials in Stroke Treatment: Targeting Oxidative Stress.Oxidative medicine and cellular longevity · 2021Review
- Improvement in the Pharmacological Profile of Copper Biological Active Complexes by Their Incorporation into Organic or Inorganic Matrix.Molecules (Basel, Switzerland) · 2020Review
- Overexpression of Central ACE2 (Angiotensin-Converting Enzyme 2) Attenuates the Pressor Response to Chronic Central Infusion of Ang II (Angiotensin II): A Potential Role for Nrf2 (Nuclear Factor [Erythroid-Derived 2]-Like 2).Hypertension (Dallas, Tex. : 1979) · 2020Article
- Loss of cAMP-dependent stimulation of isolated cilia motility by alcohol exposure is oxidant-dependent.Alcohol (Fayetteville, N.Y.) · 2019Article
- Effect of nanoformulated copper/zinc superoxide dismutase on chronic ethanol-induced alterations in liver and adipose tissue.Alcohol (Fayetteville, N.Y.) · 2019Article
- Novel Antioxidant Properties of Doxycycline.International journal of molecular sciences · 2018Article
- Direct antioxidant properties of methotrexate: Inhibition of malondialdehyde-acetaldehyde-protein adduct formation and superoxide scavenging.Redox biology · 2017Article
- Nanoformulated copper/zinc superoxide dismutase attenuates vascular cell activation and aortic inflammation in obesity.Biochemical and biophysical research communications · 2016Article
- Nanoformulated copper/zinc superoxide dismutase reduces adipose inflammation in obesity.Obesity (Silver Spring, Md.) · 2016Article
- Targeted endothelial nanomedicine for common acute pathological conditions.Journal of controlled release : official journal of the Controlled Release Society · 2015Review
- SOD1 nanozyme salvages ischemic brain by locally protecting cerebral vasculature.Journal of controlled release : official journal of the Controlled Release Society · 2015Article
- Superoxide Dismutase 1 Nanozyme for Treatment of Eye Inflammation.Oxidative medicine and cellular longevity · 2015Article
- Agile delivery of protein therapeutics to CNS.Journal of controlled release : official journal of the Controlled Release Society · 2014Review
- Neuronal uptake of nanoformulated superoxide dismutase and attenuation of angiotensin II-dependent hypertension after central administration.Free radical biology & medicine · 2014Article
- Nanocarriers for vascular delivery of anti-inflammatory agents.Annual review of pharmacology and toxicology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
Abstract
Adenoviral-mediated overexpression of the intracellular superoxide (O(2)(*-)) scavenging enzyme copper/zinc superoxide dismutase (CuZnSOD) in the brain attenuates central angiotensin II (AngII)-induced cardiovascular responses. However, the therapeutic potential for adenoviral vectors is weakened by toxicity and the inability of adenoviral vectors to target the brain following peripheral administration. Therefore, we developed a non-viral delivery system in which CuZnSOD protein is electrostatically bound to a synthetic poly(ethyleneimine)-poly(ethyleneglycol) (PEI-PEG) polymer to form a polyion complex (CuZnSOD nanozyme). We hypothesized that PEI-PEG polymer increases transport of functional CuZnSOD to neurons, which inhibits AngII intra-neuronal signaling. The AngII-induced increase in O(2)(*-), as measured by dihydroethidium fluorescence and electron paramagnetic resonance spectroscopy, was significantly inhibited in CuZnSOD nanozyme-treated neurons compared to free CuZnSOD- and non-treated neurons. CuZnSOD nanozyme also attenuated the AngII-induced inhibition of K(+) current in neurons. Intracarotid injection of CuZnSOD nanozyme into rabbits significantly inhibited the pressor response of intracerebroventricular-delivered AngII; however, intracarotid injection of free CuZnSOD or PEI-PEG polymer alone failed to inhibit this response. Importantly, neither the PEI-PEG polymer alone nor the CuZnSOD nanozyme induced neuronal toxicity. These findings indicate that CuZnSOD nanozyme inhibits AngII intra-neuronal signaling in vitro and in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.